Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies

Trial ID or NCT#

NCT01266265

Status

recruiting iconRECRUITING

Purpose

A surveillance of respiratory tract related adverse events in patients treated with Tyvaso®(treprostinil) Inhalation Solution versus other FDA approved therapies

Official Title

A Postmarketing Observational Study to Assess Respiratory Tract Adverse Events in Pulmonary Arterial Hypertension Patients Treated With Tyvaso® (Treprostinil) Inhalation Solution

Eligibility Criteria

Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. - Clinical diagnosis of PAH, WHO GROUP I - Prescribed and is currently receiving Tyvaso and/or other FDA-approved therapy for the treatment of PAH - Willing and able to provide written informed consent
Exclusion Criteria:
  1. - Previous initiation and permanent discontinuation of Tyvaso - Participation in an investigational clinical drug or device trial within 30 days of enrollment - Current or past diagnosis of lung neoplasm - Active gastrointestinal or pulmonary bleed at enrollment - Planned surgical intervention for treatment of PAH e.g., atrial septostomy or transplant
View All Criteria
Show Less

Contact us to find out if this trial is right for you.

Contact

Patricia Del Rosario
6507212408

SEND MESSAGE

View on ClinicalTrials.gov